Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H26N2O2.ClH |
Molecular Weight | 362.894 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2CC)[C@@H](O)C3=CC=NC4=CC=C(OC)C=C34
InChI
InChIKey=MULXTQKDWYBJMO-VJAUXQICSA-N
InChI=1S/C20H26N2O2.ClH/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3;1H/t13-,14-,19+,20-;/m0./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C20H26N2O2 |
Molecular Weight | 326.4326 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24068450
http://www.ajtmh.org/content/s1-12/6/473.full.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24068450
http://www.ajtmh.org/content/s1-12/6/473.full.pdf
Hydroquinidine is a pharmaceutical agent that acts as a class I antiarrhythmic agent (Ia) in the heart. Hydroquinidine is a d-rotatory alkaloid derived from cinchiona bark. It is closely related to quinidine, differing from the latter alkaloid only in containing two more atoms of hydrogen in the molecule. The drug causes increased action potential duration, as well as a prolonged QT interval. It is not approved by FDA, but marketed in Spain, France, Italy and Pakistan under the brand names Lentoquine, Sérécor LP, Idrochinidina Lirca and Austacute, respectively. Like all other class I antiarrhythmic agents, Hydroquinidine primarily works by blocking the fast inward sodium current (INa). Hydroquinidine is also used for the treatment of Malaria.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22869567 |
32.0 nM [IC50] | ||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Lentoquine Approved UseIndications: arrhythmias |
|||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Hepatitis caused by quinidine. Study of a case and review of the literature]. | 1986 Mar |
|
Safety and effectiveness of oral quinidine in cardioversion of persistent atrial fibrillation. | 2001 Dec |
|
[Adverse drug reactions in three older patients, even without changes in medication]. | 2003 Mar 29 |
|
The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids. | 2003 Sep 1 |
|
The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy. | 2014 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1933143
Curator's Comment: Recordings were made from acutely dissociated melanotrophs, obtained following the enzymatic treatment and
mechanical disruption of the neuro-intermediate lobe of the
pituitary gland of the adult male rat
Halfmaximal inhibition of IK(f) at o mV occurred with 23 + 7.8uM
hydroquinidine
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:02:46 GMT 2023
by
admin
on
Fri Dec 15 18:02:46 GMT 2023
|
Record UNII |
6BR4G8VAHM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
16211709
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | |||
|
216-024-1
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | |||
|
6BR4G8VAHM
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | |||
|
1476-98-8
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | |||
|
C014486
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | |||
|
SUB14137MIG
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | |||
|
DTXSID00933162
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | |||
|
100000077619
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | |||
|
236160
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | RxNorm | ||
|
m6113
Created by
admin on Fri Dec 15 18:02:46 GMT 2023 , Edited by admin on Fri Dec 15 18:02:46 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |